What it does
Satiety EnhancementGLP-1 Stack Add-onWeight Loss AmplificationBlood Sugar Control
Cagrilintide is a stack peptide, not a standalone. Its 7-8 day half-life produces inherently stable blood levels, so split dosing is not needed or beneficial. Position it as an amplifier for members already on a GLP-1 who want to add a second satiety mechanism. Start very low when adding to an existing GLP-1 protocol as GI side effects can be additive. The CagriSema combination (Cagrilintide plus Semaglutide) is one of the most anticipated combinations in clinical development.
Reconstitution
Mixing Instructions
1
Add 2mL bacteriostatic water to your vial.
2
Inject slowly down the glass wall. Swirl gently until clear.
3
Label with date. Refrigerate. For best results, use within 28 days of reconstitution.
Dosing Reference
Based on standard reconstitution above. All doses subcutaneous unless noted.
Based on 2mL reconstitution. 5mg vial = 2.5mg/mL. 10mg vial = 5mg/mL. Once weekly subcutaneous.
| Dose | Syringe (units) | Volume (mL) |
|---|---|---|
| 0.25mg — starter (5mg vial) | 10 units | 0.10mL |
| 0.50mg (5mg vial) | 20 units | 0.20mL |
| 1.00mg (5mg vial) | 40 units | 0.40mL |
| 0.25mg — starter (10mg vial) | 5 units | 0.05mL |
| 0.50mg (10mg vial) | 10 units | 0.10mL |
| 2.40mg (10mg vial) | 48 units | 0.48mL |
Protocol
Research Protocol
Starting dose0.16mg once weekly
TitrationIncrease every 4 weeks based on tolerance
Maintenance0.3-0.6mg once weekly
RouteSubcutaneous
FrequencyOnce weekly - 7-8 day half-life, no split needed
Best paired withSemaglutide, Tirzepatide, or Retatrutide
Cagrilintide is for research use only. When stacking with a GLP-1 agonist, begin at the lowest dose and monitor GI tolerance carefully.